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Abstract
Background: Antipsychotics are used to treat delirium in the intensive care unit (ICU) despite unproven efficacy.
We hypothesized that atypical antipsychotic treatment in the ICU is a risk factor for antipsychotic prescription at
discharge, a practice that might increase risk since long-term use is associated with increased mortality.
Methods: After excluding patients on antipsychotics prior to admission, we examined antipsychotic use in a
prospective cohort of ICU patients with acute respiratory failure and/or shock. We collected data on medication use
from medical records and assessed patients for delirium using the Confusion Assessment Method for the ICU. Using
multivariable logistic regression, we analyzed whether age, delirium duration, atypical antipsychotic use, and
discharge disposition (each selected a priori) were independent risk factors for discharge on an antipsychotic. We
also examined admission Acute Physiology and Chronic Health Evaluation (APACHE) II score, haloperidol use, and
days of benzodiazepine use in post hoc analyses.
Results: After excluding 18 patients due to prior antipsychotic use and three who withdrew, we included 500
patients. Among 208 (42%) treated with an antipsychotic, median (interquartile range) age was 59 (49–69) years
and APACHE II score was 26 (22–32), characteristics that were similar among antipsychotic nonusers. Antipsychotic
users were more likely than nonusers to have had delirium (93% vs. 61%, p < 0.001). Of the 208 antipsychotic users,
172 survived to hospital discharge, and 42 (24%) of these were prescribed an antipsychotic at discharge. Treatment
with an atypical antipsychotic was the only independent risk factor for antipsychotic prescription at discharge (odds
ratio 17.6, 95% confidence interval 4.9 to 63.3; p < 0.001). Neither age, delirium duration, nor discharge disposition
were risk factors (p = 0.11, 0.38, and 0.12, respectively) in the primary regression model, and post hoc analyses found
APACHE II (p = 0.07), haloperidol use (p = 0.16), and days of benzodiazepine use (p = 0.31) were also not risk factors
for discharge on an antipsychotic.
Conclusions: In this study, antipsychotics were used to treat nearly half of all antipsychotic-naïve ICU patients and
were prescribed at discharge to 24% of antipsychotic-treated patients. Treatment with an atypical antipsychotic
greatly increased the odds of discharge with an antipsychotic prescription, a practice that should be examined
carefully during medication reconciliation since these drugs carry “black box warnings” regarding long-term use.
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Background
Despite a dearth of evidence supporting their use, antipsy-
chotics have long been preferred agents for the treatment
of delirium in the intensive care unit (ICU). Clinical prac-
tice guidelines published in 2002 by the Society of Critical
Care Medicine (SCCM) recommended haloperidol based
on clinical experience and theoretical benefit [1]; antipsy-
chotics can improve the positive symptoms of psychosis,
many of which are similar to symptoms of hyperactive de-
lirium. Numerous surveys have documented ICU practi-
tioners’ preference for haloperidol or atypical antipsychotics
when treating delirium [2–4]. Yet, in the updated SCCM
guidelines on the management of pain, agitation, and delir-
ium published in 2013 [5], the authors concluded that there
was no evidence supporting the use of haloperidol to treat
delirium in the ICU, and the use of atypical antipsychotics
was supported only by low-quality evidence.
The use of antipsychotics, especially for prolonged periods
of time, is not without risk. Side effects include ventricular
arrhythmias, excess sedation, akathisia, and hypotension,
among others [6]. Indeed, long-term use of antipsychotics
among vulnerable populations may increase the risk of
death [7, 8], and these drugs now carry “black box warnings”
from the US Food and Drug Administration (FDA) regard-
ing treatment of dementia-related psychosis in elderly pa-
tients. The risk-to-benefit ratio for antipsychotics initiated in
the ICU may therefore increase sharply if they are continued
after hospital discharge, a practice noted in recent studies to
affect up to one-third of treated patients [9–12]. During
medication reconciliation, which plays a key role in the hos-
pital discharge process, clinicians will ideally discontinue an-
tipsychotics that were started in the ICU for delirium
(especially if delirium has resolved), but they may be reluc-
tant to do so if intensivists continued the antipsychotic upon
transfer out of the ICU. Knowledge of risk factors for being
discharged on an antipsychotic initiated for delirium in the
ICU may contribute to more informed decision making.
We conducted an observational study to identify ICU
patients most likely to be discharged from the hospital with
a prescription for an antipsychotic (typical or atypical).
Based on our clinical observation that patients discharged
on an antipsychotic are nearly always prescribed an atyp-
ical rather than typical antipsychotic, we hypothesized that
atypical antipsychotic treatment started in the ICU is an
independent risk factor for discharge on an antipsychotic.
We also hypothesized that older age, prolonged delirium,
and discharge to a location other than home would be in-
dependently associated with discharge on an antipsychotic.
Methods
Study design and population
We embedded this single-center, prospective cohort study
in the Bringing to Light the Risk Factors and Incidence
of Neuropsychological Dysfunction in ICU Survivors
(BRAIN-ICU) Study [13], which enrolled patients in
two hospitals in Nashville, TN, USA, from March 2007
to May 2010. All BRAIN-ICU subjects enrolled at
Vanderbilt University Medical Center were eligible for
the current investigation of discharge on antipsychotics
except those who were receiving antipsychotics prior to
hospital admission. Adults treated in a medical or sur-
gical ICU for respiratory failure and/or shock were en-
rolled in the BRAIN-ICU Study unless they met one or
more of the following exclusion criteria, which have
been described in detail elsewhere [13]: recent substan-
tial critical illness requiring ICU admission, conditions
that would make assessments for delirium unreliable (e.g.,
deafness, blindness, etc.), conditions that would prohibit
long-term follow-up, life expectancy <24 h, lack of informed
consent, and known or suspected severe neurologic disease.
The study protocol was approved by the Vanderbilt
University Institutional Review Board.
Clinical characteristics
We collected data on demographics and clinical charac-
teristics from the electronic medical record at the time
of enrollment and throughout the patient’s hospital stay.
These included patient age, gender, ethnicity, chronic
disease burden as per the Charlson Comorbidity Index
[14], severity of illness as per the Acute Physiology and
Chronic Health Evaluation (APACHE) II score [15] and
Sequential Organ Failure Assessment (SOFA) [16] score,
ICU type, admission diagnosis, duration of mechanical
ventilation, ICU and hospital length of stay, and receipt
of antipsychotics as well as sedatives and analgesics. Trained
research personnel assessed patients for delirium twice daily
while they were in the ICU and once daily after ICU
discharge using the Confusion Assessment Method for
the ICU (CAM-ICU) [17, 18]. We considered any day
during which at least one CAM-ICU assessment was
positive to be a day of delirium and summed these days
to determine delirium duration. Discharge disposition
(e.g., home, long-term acute care hospital, nursing home,
etc.) was extracted from the discharge orders recorded in
the medical record.
Outcome
We used discharge summaries and pharmacy records to
identify antipsychotics prescribed at the time of hospital
discharge. Specifically, we considered an antipsychotic to
be prescribed at discharge if it was included in the pa-
tient’s discharge medication summary and/or a new out-
patient prescription for the antipsychotic was recorded
in the electronic pharmacy records.
Statistical analysis
We examined baseline demographics and clinical char-
acteristics using median and interquartile range (IQR)
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for continuous variables and proportions for categorical
variables. To compare patients who were treated with
an antipsychotic with those who were not in bivariate
analyses, we used the chi-squared test for categorical
variables and the Wilcoxon-Mann-Whitney test for con-
tinuous variables. We also used these tests in bivariate ana-
lyses comparing patients discharged on an antipsychotic
with those who received an antipsychotic in the hospital
but were not discharged on the medication, i.e., the anti-
psychotic was discontinued prior to discharge.
We used multivariable logistic regression to determine
whether a priori-selected risk factors were independently
associated with discharge on an antipsychotic. To avoid
model overfitting, we limited the number of covariates
examined in our primary regression model by adhering
to the rule of thumb that a multivariable model must fit
no more than m/10 parameters (where m is the effective
sample size) for it to be reliable in similar cohorts [19].
Since 42 patients were discharged on an antipsychotic
(m = 42), we included four (42/10) covariates in our pri-
mary regression model: age, delirium duration, atypical
antipsychotic use, and discharge disposition. Additionally,
in light of results of a recent study reporting that admis-
sion APACHE II score and duration of benzodiazepine
treatment were independent risk factors for discharge on
an antipsychotic [10], we also conducted a post hoc ana-
lysis by including these covariates (one at a time) in logis-
tic regression models with the four covariates previously
specified. Finally, we also added haloperidol use to the
regression model in a post hoc analysis prompted by
the very strong bivariate association observed between
haloperidol use and discharge on an antipsychotic. We
used Stata version 10.1 for all statistical analyses and
considered a two-sided alpha of 0.05 to indicate statis-
tical significance.
Results
Of 521 patients enrolled in the BRAIN-ICU study at
Vanderbilt, we excluded 18 from the current study be-
cause they were antipsychotic users prior to hospital ad-
mission and three who withdrew after enrollment; 500
patients were therefore included in this study of anti-
psychotic prescribing (Fig. 1). Of these, 208 (42%) were
newly treated with an antipsychotic in the ICU. This in-
cluded adults of all ages, with the majority having a high
severity of illness, and most being admitted to the ICU
with sepsis/acute respiratory distress syndrome (ARDS)
(37%), after surgery (21%), or with a cardiac illness (11%),
characteristics that were similar among those who did not
receive an antipsychotic (Table 1). New antipsychotic users
were significantly more likely than nonusers to have been
mechanically ventilated at enrollment (93% vs. 83%, p =
0.002), to have had delirium (93% vs. 61%, p < 0.001), and
to have experienced a longer duration of delirium (1 vs.
5 days, p < 0.0001).
Of the 172 antipsychotic users who survived to hospital
discharge, 42 (24%) were prescribed an antipsychotic at
discharge. Only seven of these patients were delirious at
the time of hospital discharge; 28 had a normal mental
status, one was comatose, and six had an unknown mental
status because they were discharged after the 30-day
period of study assessments and medical records did not
Fig. 1 Patient Flowchart. Treatment with antipsychotics during hospitalization and at the time of hospital discharge is shown
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clearly document whether or not delirium was present at
discharge.
In unadjusted comparisons, patients whose antipsy-
chotics were discontinued prior to discharge generally
had characteristics similar to those among patients who
were prescribed antipsychotics at discharge, with the ex-
ception that patients prescribed antipsychotics at dis-
charge were much more likely to have received an
atypical antipsychotic and less likely to have received
haloperidol during their hospital stay (both p < 0.001;
Table 2). Among the 100 patients who survived to dis-
charge after treatment with an atypical antipsychotic, 82
(82%) received olanzapine during their hospital stay, 5 (5%)
received risperidone, 12 (12%) received quetiapine, and 15
(15%) received ziprasidone; 14 (14%) of these patients
received more than one atypical antipsychotic during their
hospital stay.
Among patients treated with an antipsychotic in the
hospital, receipt of an atypical antipsychotic was the
only independent risk factor for discharge on an anti-
psychotic in our primary regression model (odds ratio
(OR) 17.6, 95% confidence interval (CI) 4.9 to 63.3, p
< 0.001; Table 3). When added to the regression
model in post hoc analyses, neither admission APA-
CHE II score (OR 0.95, 95% CI 0.90 to 1.00, p = 0.07),
days of benzodiazepine use (OR 0.95, 95% CI 0.87 to
1.04, p = 0.31), nor haloperidol use (OR 0.51, 95% CI
0.20 to 1.30, p = 0.16) were associated with discharge
on an antipsychotic, and atypical antipsychotic use
remained a strong independent risk factor (p < 0.001






Age, years 58 (45–66) 59 (49–69) 0.14
Female, N (%) 141 (48.3) 95 (45.7) 0.56
Caucasian, N (%) 248 (84.9) 191 (91.8) 0.08
Baseline cognitive impairment, N (%)b 30 (10.3) 29 (13.9) 0.21
Charlson Comorbidity Index 2 (1–4) 2 (1–4) 0.33
APACHE II score at study enrollment 25 (18–31) 26 (22–32) 0.10
SOFA score at study enrollment 9 (7–13) 10 (7–12) 0.52
ICU type, N (%) 0.22
Medical 183 (62.7) 119 (57.2)
Surgical 109 (37.3) 89 (42.8)
ICU admission diagnoses, N (%) 0.29
Sepsis/ARDS 83 (28.4) 77 (37.0)
Surgeryc 65 (22.2) 43 (20.7)
CHF/MI/arrhythmia 59 (20.2) 23 (11.1)
Altered mental status 37 (12.7) 26 (12.5)
COPD/asthma 14 (4.8) 5 (2.4)
Otherd 34 (11.6) 34 (16.3)
Mechanical ventilation at enrollment, N (%) 243 (83.2) 193 (92.8) 0.002
ICU length of stay, days 3 (2–6) 9 (4–14) <0.0001
Delirium
Prevalence during study period, N (%) 178 (61.0) 193 (92.8) <0.0001
Duration, days 1 (0–3) 5 (2–8) <0.0001
aValues are shown as median (interquartile range) unless otherwise noted
bPatients with a Short IQCODE score ≥3.3 were considered to have pre-existing cognitive impairment of mild to moderate severity. We excluded patients from
study enrollment with dementia that prevented them from living independently and/or with a Clinical Dementia Rating (CDR) score of 3 or more, indicative of
severe dementia
cExcluding cardiac and neurological surgery
dIncluding cirrhosis/hepatic failure, gastrointestinal bleeding, malignancy, metabolic disarray, hemoptysis, pulmonary embolism, renal failure, and
seizure/status epilepticus
ARDS acute respiratory distress syndrome, ADL activities of daily living, APACHE II Acute Physiology and Chronic Health Evaluation II, CHF congestive heart failure,
COPD chronic obstructive pulmonary disease, IQCODE Informant Questionnaire of Cognitive Decline in the Elderly, IADL instrumental activities of daily living,
MI myocardial infarction, ICU intensive care unit, SOFA Sequential Organ Failure Assessment
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in all models) after adjusting for these additional
covariates.
Discussion
In this prospective cohort study, we found that nearly
half of all antipsychotic-naïve patients admitted with
critical illness were treated with one or more antipsy-
chotics during their ICU stay, and one out of every four
antipsychotic-treated patients was discharged on an anti-
psychotic even though the majority were no longer deli-
rious and these drugs carry “black box warnings” from
the FDA. In contrast to receipt of haloperidol, which
was not associated with discharge on an antipsychotic,
treatment with an atypical antipsychotic was independ-
ently associated with an increase in the odds of discharge
on an antipsychotic, suggesting that the use of atypical an-
tipsychotics in the ICU may place an important subset of
patients at increased risk for adverse effects after reso-
lution of critical illness. Future studies are needed to de-
termine not only the risk-benefit ratio of antipsychotic use
during critical illness but also the long-term effects of
these medications in this increasingly exposed patient
population.
Delirium—characterized by acute changes and fluctua-
tions in mental status accompanied by inattention, disor-
ganized thinking, and/or an altered level of consciousness
[20]—is common in the ICU, where up to 60% to 80% of
mechanically ventilated patients are affected. Given that
patients with delirium are at increased risk for agitation-
related adverse outcomes as well as mortality [21–23],
longer hospital stays [24], and long-term cognitive impair-
ment [13, 25], clinicians frequently treat delirium with
Table 2 Characteristics according to discharge on antipsychotic
Characteristicsa Antipsychotic discontinued before discharge
N = 130
Antipsychotic prescribed at discharge
N = 42
p
Age, years 57 (48–69) 60 (52–71) 0.20
Female, N (%) 61 (46.9) 21 (50) 0.73
Caucasian, N (%) 122 (93.9) 38 (90.5) 0.49
Baseline cognitive impairment, N (%)b 20 (15.4) 7 (16.7) 0.84
Charlson Comorbidity Index 2 (1–4) 2 (1–3) 0.35
ICU type, N (%) 0.55
Medical 75 (57.7) 22 (52.4)
Surgical 55 (42.3) 20 (47.6)
ICU length of stay, days 7 (4–14) 9 (4–12) 0.94
Delirium
Prevalence during study period, N (%) 120 (92) 40 (95) 0.52
Duration, days 4 (2–8) 6 (3–9) 0.12
Antipsychotic received, N (%)c
Atypical 61 (46.9) 39 (92.9) <0.001
Haloperidol 106 (81.5) 23 (54.8) <0.001
Discharge disposition, N (%) 0.08
Home 60 (46.2) 12 (28.6)
Long-term acute care hospital 13 (10.0) 6 (14.3)
Rehabilitation facility 38 (29.2) 15 (35.7)
Nursing home 7 (5.4) 6 (14.3)
Other 12 (9.2) 3 (7.1)
aValues are shown as median (interquartile range) unless otherwise noted
bPatients with a Short IQCODE score ≥3.3 were considered to have pre-existing cognitive impairment of mild to moderate severity. We excluded patients from
study enrollment with dementia that prevented them from living independently and/or with a Clinical Dementia Rating (CDR) score of 3 or more, indicative of
severe dementia
cPercentages sum to >100% because 50 patients received two different antipsychotics, and 14 patients received three different antipsychotics
ICU intensive care unit, IQCODE Informant Questionnaire of Cognitive Decline in the Elderly
Table 3 Risk factors for discharge on antipsychotic medication
Risk factor Odds ratio 95% Confidence
interval
p
Age, years 1.02 0.99 to 1.05 0.11
Atypical antipsychotic
received, yes/no
17.6 4.9 to 63.3 <0.001
Delirium duration, days 1.03 0.97 to 1.10 0.38
Discharge to home, yes/no 0.98 0.95 to 1.01 0.12
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antipsychotics, a practice that was recommended in older
clinical practice guidelines [1]. These medications may
offer some short-term benefit by reducing agitation [26],
but their effect on delirium and associated outcomes (in-
cluding long-term cognitive function) remains unclear.
To date, only three randomized, placebo-controlled
trials—ranging in size from 36 to 142 subjects—have ex-
amined the efficacy of antipsychotics for the management
of delirium in the ICU. In a trial of 101 mechanically ven-
tilated ICU patients [27], we examined haloperidol vs.
ziprasidone vs. placebo for the prevention and treatment
of delirium and found that neither antipsychotic changed
the number of days that patients were alive without delir-
ium or coma (p = 0.66). Similarly, Page and colleagues [26]
compared haloperidol with placebo in 142 mechanically
ventilated ICU patients and found that haloperidol had no
effect on days alive without delirium or coma (p = 0.53).
In contrast, Devlin et al. [28] compared quetiapine with
placebo for the treatment of persistent delirium in 36 ICU
patients who had not responded to haloperidol and found
that quetiapine reduced the duration of delirium (p =
0.006) and of agitation (p = 0.02). Given the small sample
sizes and conflicting results of these trials, adequately
powered, multicenter, randomized, placebo-controlled tri-
als are needed to determine whether antipsychotics are
beneficial before this class of medications can be broadly
recommended for the treatment of delirium in the ICU.
Medications started during a hospital stay are often con-
tinued at the time of hospital discharge, a care transition
when patients are at high risk of medication errors. Indeed,
both unintentional medication discrepancies—which affect
up to 70% of patients at hospital discharge [29]—and the
intentional prescription of potentially inappropriate medi-
cations [30] place recovering patients at risk for serious ad-
verse drug events at a time when they are still highly
vulnerable yet less closely monitored. Antipsychotics are
not the only class of medications that are prescribed at dis-
charge despite being no longer indicated at that time.
Scales and colleagues [31] examined four medication clas-
ses, for example, and found that all four were prescribed at
hospital discharge without a documented indication. We
specifically focused on antipsychotics in the current study
because, unlike some medications (e.g., gastric acid sup-
pressants), antipsychotics have never been proven effica-
cious in the ICU setting and their adverse effects during
chronic use are well documented. From 1995 to 2008, the
off-label use of antipsychotic medications nearly doubled
despite warnings from the FDA and others regarding ser-
ious risk [32]. It is unknown how much of this increase in
outpatient atypical antipsychotic use is related to the in-
crease in prescribing of atypical antipsychotics for delirium
in the ICU.
Our results advance and extend a growing body of evi-
dence showing that antipsychotics initially prescribed for
delirium in the ICU are often continued at the time of
hospital discharge. In a retrospective cohort study, Jasiak
et al. [9] found that 20 (34%) of 59 patients treated for
delirium with an antipsychotic in the ICU were dis-
charged from the hospital on the medication, a practice
they estimated would increase outpatient medication
costs by more than $2225 per patient per year. Several
other studies have subsequently reported that 21–29%
[10–12] of patients started on antipsychotics in the ICU
were discharged with a prescription to continue the anti-
psychotic, findings almost identical to ours. Taken to-
gether with results from a multicenter study of 164,996
hospitalizations across 71 academic medical centers in
the US [33], which reported that 1 in 10 ICU patients re-
ceived an antipsychotic during their hospital stay, these
data suggest that approximately 2.5% of the >5 million
patients discharged from US ICUs each year are pre-
scribed an antipsychotic at discharge that they were not
taking prior to their critical illness.
Our findings compliment those of other recent studies
that examined independent risk factors for discharge on
an antipsychotic started in the ICU. Rowe et al. [10]
found higher severity of illness (measured via APACHE
II score at ICU admission) and longer duration of
benzodiazepine sedation were associated with discharge
on an antipsychotic. Perhaps due to different practice
patterns, we found no association between these factors
and antipsychotic prescription at discharge in post hoc
analyses. Though atypical antipsychotic use was not
among the variables analyzed by Rowe et al., Marshall and
colleagues [12] reported results consistent with ours—ICU
patients treated with quetiapine or olanzapine were sig-
nificantly more likely to be prescribed an antipsychotic at
discharge than patients who did not receive an atypical
antipsychotic in the ICU. One might assume that treat-
ment with an atypical antipsychotic is a prerequisite for
discharge on an antipsychotic, but this is not the case
since haloperidol—the most commonly prescribed anti-
psychotic in the ICU—is available as an oral preparation.
Yet, only atypical antipsychotic use (and not haloperidol
use) was independently associated with discharge on an
antipsychotic in our study, a finding suggesting that a po-
tential disadvantage of using an atypical antipsychotic
when treating delirium in the ICU is increased risk of in-
appropriate use after discharge. In a study examining
medications prescribed at hospital discharge to 120 elderly
critical illness survivors, we found that 71% of atypical an-
tipsychotics prescribed were deemed inappropriate by an
expert panel comprised of a geriatrician, a hospitalist, and
a clinical pharmacist [30].
Strengths of this study include a prospective study de-
sign, carefully characterized risk factors including delir-
ium assessed using the well-validated CAM-ICU, and
use of multivariable regression to identify independent
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risk factors for discharge on an antipsychotic. The study
also has important limitations. As a single-center study,
its findings may be generalizable only to hospitals with
patients and providers similar to those in our medical
center. At the time of this investigation, for example,
Vanderbilt Medical Center was not yet using the elec-
tronic discharge wizard now employed to facilitate medi-
cation reconciliation. Thus, our results may be more
applicable in hospitals without formal medication recon-
ciliation practices. Given the observational study design
and the modest sample size, which limited the number
of covariates we could reliably fit in the regression
model, we cannot rule out confounding by variables not
included nor can we rule out type II error leading to a
negative finding regarding discharge location, which was
associated with antipsychotic prescription at discharge
in one recent study of ICU patients [12]. Additionally,
without clear documentation by providers of the reasons
they prescribed antipsychotics at hospital discharge, we
cannot ascertain the rationale for treatment decisions at
discharge. Some clinicians, for example, may have chosen
to prescribe antipsychotics at discharge due to an antici-
pated benefit, whereas lack of familiarity could also make
clinicians reluctant to discontinue a medication started by
another provider. Our findings may overestimate the fre-
quency of antipsychotic use after discharge since we mea-
sured prescriptions for antipsychotics but did not confirm
post-discharge adherence to these prescriptions. Finally,
the extent of long-term use and any resultant adverse ef-
fects could not be determined because of the lack of
follow-up after hospital discharge.
Conclusion
In a large cohort of patients recovering from critical ill-
ness, antipsychotics were prescribed at hospital discharge
to one out of every four patients newly treated with anti-
psychotics for delirium in the ICU, a practice most likely
to occur among patients treated with an atypical anti-
psychotic in the hospital. Not only are the efficacy and
safety of antipsychotics for delirium in the ICU unproven,
but it remains unclear which antipsychotic, if any, should
be used to treat delirium and for how long. Until clear evi-
dence from large randomized trials is available regarding
the efficacy and appropriate duration of antipsychotic use
for delirium in the ICU, this class of medication should be
used with caution. Additionally, focused efforts should be
implemented to ensure antipsychotics are appropriately
discontinued upon transitions of care in the hospital.
Key messages
 Nearly half of all antipsychotic-naïve patients admitted
with critical illness were treated with an antipsychotic
during their ICU stay.
 One out of every four patients newly treated with an
antipsychotic for delirium in the ICU was discharged
on an antipsychotic.
 Treatment with an atypical antipsychotic in the
hospital was independently associated with a 17-fold
increase in the odds of discharge on an antipsychotic.
 Treatment with haloperidol was not associated with
discharge on an antipsychotic after adjusting for
atypical antipsychotic use.
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